Navigation Links
Paresthesia in Medical News

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... investigators as possibly related to Contrave treatment. These include cholecystitis (gallbladder inflammation) (2), seizure (2), palpitations (1), paresthesia (1) and vertigo (1). The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading ...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness ...

Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease

... the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling) and pruritus (itching). About CSL Behring CSL Behring is the maker of Alpha1-Proteinase Inhibitor (Human), Zemaira. The company is a ...

Attention: Extra-hepatic manifestation of hepatitis C virus infection

... 76.5% of the patients had extra-hepatic manifestations. Common manifestations were fatigue (59.6%), renal impairment (25%), type 2 diabetes (22.8%), paresthesia (19.9%), arthralgia (18.4%), and purpura predominantly of the lower limbs (17.6%). Over 37% of the patients had cryoglobulins, and 8.8% had B-cell ...

FDA Approves New Product to Treat Von Willebrand Disease

... clinical studies, 15.8 percent of subjects and 5.7 percent of infusions were accompanied by adverse reactions, most commonly itching, pharyngitis, paresthesia (a sensation of numbness and tingling on the skin) and headache, swelling of the face, and rash and chills. Source-Bio-Bio ...
Paresthesia in Medical Technology

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), ... 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs. ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), Shoulder Pain (8 percent, 0 percent), Dyspepsia (7 percent, 0 percent), and paresthesia (6 percent, 0 percent). -- As with all therapeutic proteins, patients may develop antibodies to the therapeutic protein. About Amgen ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%). Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs. ...

Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

... following treatment-related adverse reactions were reported in 1 percent of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling) and pruritus (itching). Zemaira is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious ...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... persistent neuropathy occurred in 48% (all grades) and 6% (grade 3/4) of patients. In patients with stage II and III colon cancer, paresthesia was seen in 92% (all grades) and 13% (grade 3/4) of patients; 21% (all grades), 0.5% (grade 3/4) had residual paresthesia at 18-month ...
Paresthesia in Medical Products

Precision SCS System

Description:... PRECISION represents a major advance in neurostimulation. With PRECISION, paresthesia can be tightly focused to cover pain. This is done by smoothly moving stimulation where you need it, anywhere along the lead or between ...
Company:Advanced Bionics Corporation
Paresthesia in Medical Dictionary

Paresthesia

... paresthesia : Abnormal sensations such as burning, tingling, or a "pins-and-needles" feeling. paresthesia may constitute the first group of symptoms of ... side effect that does not worsen with time. paresthesia s ( Numbness and Tingling ) Paroxysm al ...

Peripheral neuropathy

... pains and wind , which is reversible when intake is reduced.9 ... paresthesia may constitute the first group of symptoms of peripheral neuropathy , ... a limited drug side effect that does not worsen with time. Circumoral paresthesia affects the area around the mouth. Tacticon Noninvasive hand -held ...

Stimulus

... a small hammer , the lower leg kicks forward strongly. CIRCUMORAL paresthesia : An abnormal touch sensation, such as burning or prickling around the mouth, often in the absence of an external stimulus . See paresthesia . They also help practitioners gauge physical feedback to a stimulus ...

Anterior

... removed half my colon and most of my rectum , and joined up the remaining colon to what's left of my rectum . general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; paretic neurosyphilis ; pareunia; parfocal objectives; pargasite; pargyline; pargyline ...

Heat intolerance

... skin , and heat intolerance . Mucous membrane involvement may result in a foul- smell ing nasal discharge . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Impotence

... ; parent material; parents; parepicele; par epididymis ; parepithymia; parerethisis; parergasia; paresis ; paresis , general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; ... Impotence (Erectile Dysfunction) Im pulse -Control Disorders Inborn Errors of ...

Muscle aches

... , vomiting , and diarrhea . Patients also may bleed or bruise easily, get a skin rash , or have swelling . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Muscle cramps

... fluid (and electrolyte) balance, and causes nausea , vomiting , muscle cramps , confusion and convulsions . Numbness Abnormal sensations ( paresthesia ); "pins and needles" Painful sensations Muscle weakness Muscle cramps or muscle aches Heat intolerance , especially after exercise ...

Neuralgia

... post -herpetic neuralgia . People with intra ctable post -herpetic pain often become depressed. Acute and postherpetic neuralgia Painful paresthesia and dysesthesia. Thoracic and cranial nerve V are most common. This is a condition called postherpetic neuralgia . It is most likely to ...

Neurosyphilis

... ; parent material; parents; parepicele; par epididymis ; parepithymia; parerethisis; parergasia; paresis ; paresis , general; Pare's suture ; paresthesia ; paresthetic; parethmoid; paretic; paretic impotence ; paretic neurosyphilis ; ... 2 A form of neurosyphilis ( syphilis affecting the ...

More>>

Paresthesia in Biological Technology

New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation

... 3/4) of patients. In patients with stage II and III colon cancer, paresthesia was seen in 92% (all grades) and 13% (grade 3/4) of patients; 21% (all grades), 0.5% (grade 3/4) had residual paresthesia at 18-month follow-up -- Hepatotoxicity, as evidenced in the adjuvant ...
Other Contents
(Date:7/27/2014)... 2014 The report, “Oil Filter & ... & HCVs), Market Type (OE & Aftermarket), Filter Type ... Geography - Industry Trends & Forecast to 2018”, defines ... market with analysis and forecasting of the global volume ... estimated to reach a revenue of $6.1 billion in ...
(Date:7/27/2014)... The report provides market analysis of the "Actuator ... Aviation And Defense Aviation Landing Gear, Flight Control, ... - 2019." The report covers the key market ... during the study period. It also discusses the ... prevailing in the global market. , Browse 52 ...
(Date:7/27/2014)... Although Cigarette and Tobacco Product ... companies, heavy government regulation results in extremely fierce ... “Demand for cigarettes has declined over the past ... anti-smoking campaigns, increasing regulation and higher excise taxes.” ... fall at a compound annual 0.8% over the ...
(Date:7/27/2014)... Ticket Down is a reputable source for ... Miami, FL at the Sun Life Stadium on August 4th. ... In the opening game, Olympiacos from Superleague Greece defeated AC ... early lead in their group. Six other teams will also ... Manchester City, Manchester United, AS Roma, Liverpool FC, Inter Milan, ...
(Date:7/27/2014)... Discount-Dress.com is a leading online supplier ... current and prospective customers. Each of its top quality ... a team of considerate designers; they are now striving ... solutions. , Recently, the firm has announced its ... top it all off, these brand-new and fashionable items ...
Breaking Medicine News(10 mins):Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 3Health News:New Cocktail Party Dresses From Leading Online Supplier Discount-Dress.com Receive National Attention 2
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
Other TagsOther Tags